Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Si...
Dentsply Sirona to Participate in Upcoming Investor Conferences CHARLOTTE, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 2:35 pm ETBaird Global Healthcare Conference on September 9, 2025, at 1:25 pm ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About ...
Dentsply Sirona Reports Second Quarter 2025 Results Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impactGAAP gross margin of 52.4%, GAAP net loss per share of ($0.22)Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted EPS of $0.52Executed $550 million debt offeringReaffirmed FY25 outlookLeadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025 CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Si...
Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 Outlook CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the “Board”), has been appointed President and Chief Executive Officer, effective A...
Dentsply Sirona to Host Second Quarter Conference Call on August 7th CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET to review its financial results for the second quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company’s website at prior to t...
Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the “notes”). The Offering is expected to close on June 12, 2025, subject to customary closing conditions. The notes will bear interest at a fixed rate of 8.375% per year until September 12, 2030 (the “First Reset Date”). On and after the Fi...
Moody's Ratings (Moody's) assigned a Baa3 rating to Dentsply Sirona Inc.'s ("Dentsply Sirona") proposed offering of junior subordinated notes ("hybrid"). At the same time, we affirmed Dentsply Sirona's Baa2 issuer rating, Baa2 senior unsecured rating and Prime-2 commercial paper rating. The outlook ...
Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader ...
Dentsply Sirona Declares Quarterly Cash Dividend CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service t...
Dentsply Sirona to Participate in the 2025 Stifel Jaws & Paws Conference CHARLOTTE, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 2025 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 28, 2025, at 9:45 am ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at . About Dentsply Sirona Dentsply Sirona is th...
Dentsply Sirona Reports First Quarter 2025 Results Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results f...
Dentsply Sirona to Host First Quarter Conference Call on May 8th CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company’s website at Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company’s we...
Moody's Ratings (Moody's) revised Dentsply Sirona Inc.'s ("Dentsply Sirona") outlook to negative from stable. At the same time, we affirmed Dentsply Sirona's Baa2 issuer rating, Baa2 senior unsecured rating and Prime-2 commercial paper rating. The revision of the outlook to negative reflects our v...
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of exp...
A director at Dentsply Sirona Inc bought 15,142 shares at 16.510USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2025 CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 11, 2025, at 3:00 pm ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About Dentsply Si...
Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (...
Dentsply Sirona Initiates Review of Strategic Alternatives for Wellspect Healthcare CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business (“Wellspect”). Wellspect is a leading provider of bladder and bowel management care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.